Hepatitis B Surface Antibody Blood Test: Normal Ranges, Causes & What Your Results Mean

What Is Hepatitis B Surface Antibody?

Hepatitis B surface antibody (anti-HBs) is a protective protein produced by your immune system in response to the hepatitis B surface antigen (HBsAg) - the outer protein coat of the hepatitis B virus. The presence of anti-HBs in your blood indicates that you have developed immunity to hepatitis B, either through vaccination or by recovering from a natural infection.

Anti-HBs is the only hepatitis B marker that appears after successful vaccination. When you receive the hepatitis B vaccine, your immune system is exposed to a synthetic version of the surface antigen, prompting it to produce anti-HBs antibodies. These antibodies can then neutralise the actual virus if you are ever exposed, preventing infection.

In the context of natural infection, anti-HBs typically appears after the surface antigen (HBsAg) has been cleared from the blood - a process called seroconversion. The development of anti-HBs following acute hepatitis B signals that the infection has been successfully resolved and the individual is now immune.

Anti-HBs levels are measured quantitatively in milli-international units per millilitre (mIU/mL), which allows healthcare providers to assess the strength of your immune protection and determine whether booster vaccination is needed.

Why Is Hepatitis B Surface Antibody Tested?

Anti-HBs testing is performed for several important clinical and occupational reasons:

• Post-vaccination immunity assessment: After completing the hepatitis B vaccination course, anti-HBs testing confirms whether the vaccine has produced an adequate immune response. This is particularly important for healthcare workers, as the NHS requires documented immunity for those with exposure-prone procedures.
• Healthcare worker screening: NICE and the Department of Health mandate anti-HBs testing for healthcare workers to confirm vaccine response. A level of 10 mIU/mL or above is considered protective, though levels above 100 mIU/mL are preferred for exposure-prone procedures.
• Post-exposure assessment: Following a needlestick injury or other potential hepatitis B exposure, anti-HBs testing helps determine whether the exposed individual has sufficient immunity and guides the need for post-exposure prophylaxis.
• Hepatitis B panel interpretation: Anti-HBs is part of the standard hepatitis B serological panel. Together with HBsAg and anti-HBc, it enables clinicians to distinguish between vaccination immunity, resolved natural infection, chronic infection, and susceptibility.
• Immunosuppressed patient monitoring: Patients on chemotherapy, biological therapies, or post-transplant immunosuppression may need anti-HBs monitoring, as declining levels can indicate increased vulnerability to HBV infection or reactivation.
• Booster vaccination decisions: Over time, anti-HBs levels may decline. Testing determines whether a booster dose is needed to restore protective immunity.

Normal Ranges

Anti-HBs results are reported quantitatively in mIU/mL. The following table shows how results are interpreted:

Anti-HBs Level (mIU/mL)	Interpretation	Clinical Action
< 10	Non-immune / inadequate response	Vaccination or booster recommended if at risk
10 – 99	Immune (adequate protection)	Protective; booster may be considered for high-risk individuals
100 or above	Immune (strong protection)	Good response; no immediate action needed

Key points regarding interpretation:

• The internationally accepted threshold for protective immunity is 10 mIU/mL.
• For UK healthcare workers undertaking exposure-prone procedures, the Department of Health recommends a post-vaccination level of 100 mIU/mL or above.
• Approximately 5-10% of vaccinated adults are "non-responders" who fail to achieve adequate anti-HBs levels after the standard three-dose vaccination course. These individuals may benefit from an additional course or alternative vaccine formulations.
• Anti-HBs levels naturally decline over time, but immunological memory (mediated by memory B cells) typically persists even when antibody levels fall below 10 mIU/mL. Most immunocompetent individuals who initially responded to vaccination remain protected against clinical disease.

What Do High Hepatitis B Surface Antibody Levels Mean?

High anti-HBs levels are a positive finding, indicating strong immunity against hepatitis B:

• Successful vaccination: A strong anti-HBs response (100 mIU/mL or above) after completing the vaccination course indicates excellent immune protection. This is the desired outcome and typically means long-lasting immunity.
• Recent booster vaccination: Anti-HBs levels peak shortly after vaccination or booster doses and may be very high (sometimes exceeding 1,000 mIU/mL) in the weeks following immunisation.
• Resolved natural infection: Individuals who have recovered from acute hepatitis B often develop high anti-HBs levels, reflecting a strong immune response that cleared the virus. When combined with positive anti-HBc, this pattern confirms natural immunity.
• Hepatitis B immunoglobulin (HBIG): Passive antibodies from HBIG administration (given for post-exposure prophylaxis or to newborns of HBsAg-positive mothers) temporarily produce high anti-HBs levels. These wane over weeks to months as the passive antibodies are metabolised.
• Anamnestic response: Even if anti-HBs levels have declined over time, re-exposure to HBsAg (through natural exposure or a booster dose) can trigger a rapid and strong anamnestic (memory) response, producing very high antibody levels.

What Do Low Hepatitis B Surface Antibody Levels Mean?

Low or undetectable anti-HBs levels have several possible explanations:

• No vaccination or exposure: If you have never been vaccinated against hepatitis B and have never been infected, anti-HBs will be undetectable. You are susceptible to infection and vaccination is recommended if you are at risk.
• Vaccine non-response: Approximately 5-10% of adults do not mount an adequate antibody response to the standard hepatitis B vaccine. Risk factors for non-response include age over 40, obesity, smoking, immunosuppression, chronic kidney disease, and coeliac disease.
• Waning immunity: Anti-HBs levels naturally decline over time after vaccination. Studies show that 15-50% of vaccine responders may have anti-HBs levels below 10 mIU/mL within 5-15 years. However, most retain immunological memory and remain protected against clinical disease.
• Active chronic hepatitis B: In chronic hepatitis B infection, HBsAg is persistently present and anti-HBs does not develop - the virus continues to produce surface antigen that overwhelms the antibody response.
• Immunosuppression: Chemotherapy, HIV infection, organ transplant medications, and biological therapies (particularly anti-CD20 agents like rituximab) can suppress anti-HBs production and reduce existing levels.
• Early acute infection: During the acute phase of hepatitis B infection, anti-HBs has not yet developed. There may be a "window period" where HBsAg has been cleared but anti-HBs has not yet appeared - anti-HBc IgM is the key diagnostic marker during this period.

How to Improve Your Hepatitis B Surface Antibody Levels

Improving anti-HBs levels centres primarily on vaccination and immune health:

Vaccination

• Complete the full course: The standard hepatitis B vaccine schedule in the UK is three doses at 0, 1, and 6 months. Ensure you complete all three doses for the best chance of developing protective immunity.
• Booster doses: If your anti-HBs has fallen below 10 mIU/mL and you remain at risk, a single booster dose often restores protective levels. If the booster does not elicit a response, a further full course may be recommended.
• Alternative vaccines for non-responders: Higher-dose formulations (such as Fendrix, which contains a novel adjuvant) may be offered to individuals who failed to respond to standard vaccination, including patients with chronic kidney disease.
• Intradermal vaccination: Some evidence suggests that intradermal (rather than intramuscular) administration may improve response rates in non-responders.

Supporting Immune Function

• Maintain a healthy weight: Obesity is a recognised risk factor for vaccine non-response. Achieving a healthy BMI can improve immune function and vaccine responsiveness.
• Stop smoking: Smoking impairs immune function and is associated with reduced vaccine response. Quitting can improve your body's ability to mount an effective antibody response.
• Ensure adequate nutrition: Vitamins A, C, D, E, zinc, and selenium all play roles in immune function. A balanced diet rich in fruits, vegetables, lean protein, and whole grains supports optimal immune responses.
• Manage chronic conditions: If you have diabetes, chronic kidney disease, or HIV, optimising management of these conditions can improve vaccine responsiveness.
• Exercise regularly: Moderate regular exercise has been shown to enhance immune function, including antibody responses to vaccination.

When Should You Get Tested?

Anti-HBs testing is recommended in the following situations:

• You are a healthcare worker requiring evidence of hepatitis B immunity for your role
• You have completed a hepatitis B vaccination course and need to confirm your immune response (typically tested 1-2 months after the final dose)
• You have had a potential exposure to hepatitis B (needlestick injury, sexual contact with an infected person)
• You are about to start immunosuppressive therapy and need to assess your hepatitis B immunity status
• You are a kidney dialysis patient requiring regular monitoring of vaccine-induced immunity
• You were vaccinated more than 10 years ago and want to check whether a booster is needed
• You are in a high-risk group and want to confirm your immune status

The UK immunisation schedule now includes hepatitis B vaccination for all infants (introduced in 2017). For adults, vaccination is recommended for at-risk groups including healthcare workers, people who inject drugs, men who have sex with men, sex workers, household and sexual contacts of known carriers, and travellers to endemic areas.

Which Lola Health Tests Include Hepatitis B Surface Antibody?

Lola Health offers comprehensive blood testing that includes markers relevant to liver health and immune status:

• Peak Insights - Our most extensive health panel, providing a thorough overview of your health including liver function and immune markers.
• Vital Check — A detailed wellness assessment covering essential biomarkers to help you understand your immune and liver health.
• Core Health — An essential health check covering foundational biomarkers to monitor your overall wellbeing and identify potential concerns.

All Lola Health tests use venous blood draws performed by qualified phlebotomists for medical-grade accuracy. Results are reviewed by GP-certified professionals and delivered with personalised health recommendations.